With a market value of $86.9 billion, Ecolab Inc. (ECL) is a St. Paul, Minnesota-based company that provides water, sanitation, and infection prevention solutions and services.
Companies valued at $10 billion or more are typically classified as “large-cap stocks,” and Ecolab fits the label perfectly, with a market cap in excess of that range, indicating its size, influence, and dominance in the specialty chemicals industry. The company’s strengths lie in global, long-term customer relationships, regulatory expertise, and data-driven technologies that help customers improve operational efficiency, reduce water and energy use, and maintain high safety and sustainability standards.
The hygiene and infection prevention solutions provider is currently trading just shy of its 52-week high of $309.27 reached on February 24th. Shares of ECL have risen 12.1% over the past three months, trailing the iShares U.S. Basic Commodities ETF ( IYM ) which has risen 28% over the same time frame.
Moreover, on a YTD basis, ECL’s shares are up 17.5% compared to IYM’s 22.5% rise. In the long term, ECL has gained 15.4% over the past 52 weeks, trailing IYM’s 37.6% gain over the same time frame.
Confirming its bullish trend, ECL has been trading above its 200-day and 50-day moving averages since early January.
On February 10, ECL shares rose 4% after better-than-expected Q4 earnings were released. The company’s total revenue rose 4.8% year-over-year to $4.2 billion, beating consensus estimates by a slight margin. In addition, adjusted EPS of $2.08 was a 14.9% improvement over the same period last year, versus analyst expectations of $2.06. The company is currently reaching all-time highs in early 2026, largely due to its defensive business model. Hospitals, hotels and food plants need sanitation services regardless of whether the economy is growing or slowing down.
ECL’s competitor, DuPont de Nemours, Inc. (DD) has also underperformed, which is up 47.8% over the past 52 weeks and 24.5% on a YTD basis.
Despite Ecolab’s recent lackluster performance, analysts are moderately optimistic about its prospects. The stock has a consensus rating of “average buy” from the 28 analysts that cover it, and an average price target of $323.52 suggests a 4.9% premium to its current price level.
As of the date of publication, Niharika Jain held no positions (either directly or indirectly) in any of the securities mentioned in this article. All information and data in this article is for informational purposes only. This article was originally published on Barchart.com
